fbpx Skip to main content

Members in Action

Biocom is proud of the swift actions of our member companies and the work they are doing to address COVID-19. Check this page for the latest information, guidance and updates from Biocom and our partners regarding the novel coronavirus (COVID-19) as it relates to California’s life science industry.


  • Workplace surveillance program for COVID-19 using CovClear, a rapid antigen test.


  • Doctors in China have started using a combination of AbbVie Inc.’s HIV drugs ritonavir and lopinavir at hospitals. A clinical trial is assessing whether the combination, sold under the brand name Kaletra, is more effective than an antiviral medicine known as interferon-alpha 2b in treating patients – Read More – Bloomberg


  • Partnered with Fortune 500 companies and the American Hospital Association to donate AccendoWave Hospital Grade Cell Phone UV Sanitizing and Charging Carts to Hospital ED’s, L&D, and ICU’s.
  • Preliminary study: The Coronavirus May Linger On Plastic And Stainless Steel For Days – Read More
  • UV-C Sterilization PPE and Devices Solution| Pricing
  • COVID-19 Infection Control Solution for Hospitals; Providing Hospital Grade Cell Phone UV Sanitizing and Charging Carts to Hospital ED’s, L&D, and ICU’s. Hospital grade UV cell sanitizing for 72 cell phones in an hour – Learn More
  • Infection Control: Linking Corporations with Hospitals – Read More

Aethlon Medical

Aethlon Medical received the OK from the FDA to test its blood-filtering device on severe COVID-19 patients – Read More

Agena Bioscience

  • Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel – Learn More
  • Agena Bioscience Launches High-Throughput, Low-Cost SARS-CoV-2 Detection Panel in Europe with CE-IVD Marking – Learn More


  • Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 – Read More
  • Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts – Read More

Ansun Biopharma

  • Ansun Seeks to Reprise Chinese Covid-19 Drug Trial Results in U.S. – Read More
  • Report: 16 COVID-19 Clinical Trials Showing Positive Results So Far – Read More
  • Ansun Biopharma Takes Aim at COVID-19 with Experimental Influenza Treatment – Read More
  • Announced Positive Results from Investigator Initiated Trial for novel COVID-19 Treatment – Read More
  • Enrolled our First Patient in Proof of Concept Trial of our Drug for the Treatment of COVID-19 – Read More


  • Aragen is producing reagents that are incorporated into COVID-19 test kits.


  • Argonaut has immediate aseptic fill/finish capacity for COVID-19 vaccines and therapies – Learn More

Atara Biotherapeutics

  • Atara Biotherapeutics has authored a white paper detailing the company’s proactive response to the COVID-19 pandemic entitled “Leading Through Uncertainty: Transforming, Advancing, and Adapting During the ‘New Normal.’” As a small pre-commercial biotech organization with less than 500 employees, Atara ensured business continuity throughout the pandemic by enacting a number of safeguards, inclusive of an on-site monitoring program, enhanced cleaning and Personal Protective Equipment (PPE), as well as rapid and transparent communication and educational materials for staff. Read more here.

Augmenta Bioworks

  • Working on treatments for COVID-19.


  • BillionToOne has developed a highly accurate and cost-effective novel COVID-19 test protocol, unlocking more than one million testing capacity per day in the United States alone – Read More


  • To support public efforts, performing COVID-19 testing in a high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego, with specialized, licensed molecular lab staff that have been trained in performing the COVID-19 testing – Learn More
  • For further questions, please email [email protected] or call (888) 332-7729.

BioLink Depot

  • Donating Personal Protective Equipment to Highland Hospital – Learn More

Bristol-Myers Squibb

  • Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. – Read More


  • Launched trials of drug to treat COVID-19 pneumonia. Anti-inflammatory drug could help those with severe pneumonia avoid going on ventilators. – Read More


  • Turning research toward fighting Coronavirus Pandemic – Read More


Raised $38 million to pursue low-cost testing platform for coronavirus – Read More


  • Cidara is developing a new generation of long-lasting antiviral drugs, Cloudbreak antiviral Fc-conjugates (AVCs), that directly inhibit viral replication while simultaneously engaging the immune system. Its lead program targets influenza prevention and treatment. Regarding COVID-19, Cidara is developing AVCs to provide a single dose, long-lasting treatment and prevention option that reaches the lung and targets the virus directly, in a fundamentally novel way versus vaccines and monoclonal antibodies.
  • Cidara has been included in COVID-19 databases that are tracking those who are developing vaccines or treatments:

City of Hope

  • City of Hope Researchers are Developing a COVID-19 Vaccine – Read More

COVID-19 Response Task Force

  • Los Angeles members including Lab Launch, Caltech, Karma Biotechnologies, as well partners at MarsBio and more, have created a taskforce to combat COVID-19
  • They are doing this by seeking proposals for ideas on the following: Public safety and prevention, Operational response, Vaccine development, Treatment mechanisms, and Point of care diagnostics – Learn More
  • LA County’s First Bioscience Fund Could Fuel COVID-19 Testing and Vaccine – Read More

CSL Behring

  • CSL teams up with Takeda to create virus plasma treatment – Read More

Cue Health

  • Cue Health hauls in $100M to develop rapid viral tests – Read More
  • San Diego’s Cue Health nets $13M from U.S. health agency to develop rapid coronavirus test – Read More

Curative Medical

  • Designing and manufacturing med devices for diagnosis & treatment of cardiopulmonary diseases & sleep disorders – Read More

Diagnostics for the Real World

  • Diagnostics for the Real World has developed new rapid diagnostic test for COVID-19 – Read More

Distributed Bio

  • Three independent laboratories, including one at Stanford University, have confirmed that multiple Centivax antibodies previously used in treating SARS, are potent neutralizers of COVID-19 – Read More
  • Coronavirus spreads faster than influenza, scientist from Netflix’s ‘Pandemic’ says – Read More

Drug Delivery Experts

  • Maintaining laboratory operations for some critical pharmaceutical drug development programs for client projects.
  • Donating PPE for clinical use (gloves, masks, gowns).
  • Continuing the work to complete a sterile fill finish suite (available July 2020) so that we can serve as one of the 4 or 5 GMP suites for injectable clinical supplies and GLP preclinical supplies in the San Diego area.

eClinical Solutions

  • eClinical Solutions has developed elluminate COVID-19 Analytics based on industry and client feedback to help sponsors manage the impact of COVID-19 on their ongoing trials. These analytics provide trial managers with the real-time clinical and operational insights needed to proactively manage the impact of COVID-19 on patient safety and data quality. elluminate COVID-19 Analytics will also help increase oversight and regulatory compliance with recommendations made in the recent FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic. These analytics are complimentary for existing clients and are available to new clients at a reduced rate for implementation within weeks.
    • Proactively Mitigates COVID-19 Risks on Your Trials
    • Improves Oversight and Regulatory Compliance
    • Can be Rapidly Implemented for Ongoing Trials
  • Learn More | Press Release | COVID-19 Analytics Webinar | elluminate COVID-19 Analytics Fact Sheet | Read More

eFFECTOR Therapeutics

San Diego biotech’s anti-tumor molecule slows coronavirus, lab study finds – Read More

Enable Biosciences

  • Enable Biosciences is working on ultrasensitive blood antibody tests for COVID19. More on their research can be found on their website here.


  • FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19 – Read More


  • Launched high-speed COVID-19 antibody test; The first instrument-based, rapid test uses multi-antigen approach – Read More
  • Developing SARS-CoV-2 Serology screening panel available in early April
  • Working with major healthcare institutions on employee screening, clinical trials and patient screening
  • COVID-19 Solution


  • GigaGen’s Surge technology uses single-cell sequencing to “capture and recreate” whole libraries of antibodies from recovered COVID-19 patients – Read More


  • Reports preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a five-day dosage of remdesivir improved – Read More
  • Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment – Read More
  • Assisting in development and testing of therapies (trial).
  • Working with Chinese health authorities to set up a randomized clinical trial in the country of its experimental antiviral drug remdesivir (used for Ebola), which has shown some potential in animal studies against the related coronaviruses MERS and SARS.
  • Bring deep experience in antiviral research and development and the global reach that many of the dozen or so biotechs working on coronavirus therapeutics lack. Has drawn attention for the potential of its antiviral drug remdesivir (now are accelerating lab testing of this drug to see its affects against coronavirus).
  • Read More – BioPharma Dive
  • Read More – The Economist


  • Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19 – Read More


  • Joining Sanofi in an unprecedented COVID-19 collaboration – Read More
  • Assisting in development and testing of therapies.
  • One of the world’s largest producers of vaccines, has made its vaccine adjuvant technology (makes vaccines more effective & boosts immunity) available to companies and universities partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) on coronavirus vaccine development.
  • Brings deep experience in antiviral research and development and the global reach that many of the dozen or so biotechs working on coronavirus therapeutics lack.
  • In theory, the adjuvant should cut the amount of antigen that is needed to create effective vaccines. That benefit, known as antigen sparing, is particularly sought after during pandemic outbreaks as it enables more people to be vaccinated using available antigen supplies.
  • Coalition for Epidemic Preparedness Innovations (backed by Bill & Melinda Gates Foundation).
  • Australia’s University of Queensland is the first CEPI-partnered group to formalize an agreement with GSK, which will supply its AS03 adjuvant system to the university. – Read More – Fierce Biotech


  • Helix lab switches gears to create COVID-19 tests – Read More


  • Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test – Read More
  • Illumina partners with the San Diego Unified School District and the San Diego Foundation, donates $1M to San Diego Students, Frontline Workers – Read More
  • Made Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19 – Read More
  • IDbyDNA and Illumina have partnered to bring next-generation sequencing (NGS) workflows to the global microbiology market to combat the COVID-19 pandemic – Read More

Immix Biopharma

  • Cancer research company which has pivoted to combat COVID-19. Immix Biopharma has been collaborating with MannKind to develop possible treatment options. Immix plans to create a prevention strategy to reduce reinfection risk as well.
  • Read more: UCLA | Nasdaq

Inovio Pharmaceuticals

  • The Coalition for Epidemic Preparedness Innovations (CEPI) grants $6.9 million funding to INOVIO and IVI to conduct clinical testing in Korea for INOVIO’s COVID-19 vaccine candidate based on their well-established DNA platform technology – Read More | SDUT
  • San Diego company Inovio initiates phase 1 clinical trial of its COVID-19 vaccine with first dose – Read More
  • The Coalition for Epidemic Preparedness Innovations signed contracts with drugmakers including Moderna and Inovio Pharmaceuticals Inc. as early as Jan. 22 to expedite work. – Read More – Bloomberg
  • Inovio Pharmaceuticals plans first dosing of patients in trial of DNA COVID-19 vaccine candidate on Monday 4/6 – Read More

Johnson & Johnson

  • J&J Presents “The Road to a Vaccine,” a weekly live series exploring the complexity of the search for a COVID-19 vaccine. First episode Tues 4/14 9am PDT – Read More
  • Working on production of a COVID-19 vaccine. Received $450 Million Coronavirus vaccine contribution with U.S. government – Read More

La Jolla Institute for Immunology

  • In search of antibodies that can treat COVID-19, a strategy that public health officials say could end up saving countless lives as the pandemic unfolds – Read More


  • Wants to help create better COVID-19 blood tests by targeting the spike proteins on the virus which infect healthy cells – Read More

Leading BioSciences

  • Obtained FDA clearance for their phase 2 COVID-19 study (Read More) which prompted a short article in the UT. The central thesis behind the founding of Leading BioSciences is that powerful digestive enzymes, leaking from a compromised intestinal membrane, trigger a dangerous cascade of inflammation, cytokine storm, autodigestion of tissues, and organ failure (e.g., ARDS and MODS). With growing reports on the involvement of the GI tract and the prevalence of peripheral organ damage in COVID-19 patients, it is likely that many of the most severe outcomes of this disease are caused or exacerbated by a loss of intestinal barrier integrity. LB1148, their lead product, was developed to preserve the integrity of the GI tract and block the damaging activity of leaking digestive enzymes. Leading BioSciences’ unique approach to treating COVID-19 gaining momentum.
  • Investigating their lead drug, LB1148, as a potential therapy for patients with coronavirus-associated acute respiratory distress syndrome (ARDS) and multiorgan dysfunction syndrome (MODS) – Read More
  • Investigational drug, LB1148, is being developed to reverse organ disfunction in critically ill patients, including, potentially, those infected with COVID-19
  • LB1148 is a novel formulation of the well-characterized protease inhibitor tranexamic acid that has demonstrated safety in clinical studies and increased survival in multiple models acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS)

Ligand Pharmaceuticals

  • Using technology to boost drug solubility as part of Gilead’s antiviral drug remdesivir that’s undergoing testing for COVID-19 – Read More


  • Sharing methods on how to prevent infection, the current R&D status on potential treatment drugs and vaccines, healthcare institutions, universities, venture companies, as well as updates on the COVID-19 situation and a summary of major publications.
  • Learn more on Link-J’s website


  • Lucidant Polymers is a specialty polymers manufacturer which directly supplying materials for RNA and DNA sequencing.  Data derived from that is key to understanding the spread of coronavirus, its mutation rates and should provide vital clues on the efficiency of any potential vaccine.

Mammoth Biosciences

  • Given the global health emergency, rapid transmission, and severe respiratory disease associated with the outbreak of the 2019 novel coronavirus (SARS-CoV-2), Mammoth Biosciences has reconfigured our ​DETECTR platform to rapidly and accurately detect SARS-CoV-2 using a visual lateral flow strip format within 30 minutes from sample to result – Read More – Mammoth Biosciences

Mercaptor Discoveries

  • Using its Proprietary Neurotherapeutic Platform to Develop Treatment for COVID-19 – Read More

Mobile Xpress Clinics

  • Created expert mobile testing to bring rapid, comprehensive COVID screening and logistics to employers – Learn More | Website


  • Nirmidas recognized as part of StartX Med COVID-19 Task Force – Read More


  • Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2 – Read More
  • Pfizer begins human clinical trials in US of COVID-19 vaccine candidate – Read More
  • Pfizer identifies lead COVID-19 therapeutic candidate, aims to be in clinic in summer; expects to start vaccine trials this month – Read More
  • Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
  • Medical Professionals Across Merck & Co., Inc., Pfizer Inc., And Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients amid Covid-19 Pandemic – Read More


  • Testing drug to keep COVID-19 patients off ventilators – Read More

PolyPeptide Group

  • PolyPeptide GroupSelected by Novavax toManufacture CriticalIntermediates ofMatrix-M™ Adjuvant for its COVID-19Vaccine – Read More
  • PolyPeptide Group is actively engaging in helping find treatments and vaccines for COVID-19 – Read More


  • ProSciento is conducting clinical trials for COVID-19 in healthy subject populations at its clinical research unit (CRU) in Chula Vista, CA. ProSciento’s CRU includes on-site clinical, subject recruitment, and pharmaceutical teams that are widely recognized for their expertise in early phase studies. The facility has 30,000 square feet of treatment and related office space, including 30+ treatment beds, CLIA-certified laboratory, and USP 797/800 standard clean room. The CRU has in-house extended stay capabilities of up to 8 weeks. – Learn More


  • Supporting local and global communities through Community and Charitable Donations – Learn More

Sanford Burnham Prebys Medical Discovery Institute

  • $10M grant supports Sanford Burnham Prebys testing of broad-spectrum antivirals to combat COVID-19 – Read More
  • San Diego Scientists Test Thousands of COVID-19 Drugs, Say Some Look Promising – Read More

Sanguine Biosciences

  • In-Home Specimen Collection for COVID-19 – Read More


  • Joining GSK in an unprecedented COVID-19 collaboration – Read More

Scanwell Health

  • An At-Home Coronavirus Test May Be on the Way in the U.S. – Read More

SCREEN Consortium

  • The San Diego COVID-19 REsearch Enterprise Network (SCREEN) is a grassroots-driven, multi-institutional effort with researchers and clinicians from UCSD, Salk, Scripps, SDSU, Sanford-Burnham, LIAI and Rady’s Children Hospital
  • It provides the community with COVID-19 information and funding announcements, sparks and coordinates local research collaborations and connects immediate local problems with rapid solutions.
  • The Consortium uses Slack as a software platform to connect more than 800 academic scientists and clinicians. Learn more here, or email [email protected] 


SDG&E’s Coronavirus Response: Supporting Customers Through these Tough Times – Read More


  • SGI-DNA is empowering researchers with the tools and resources they need to develop vaccines, therapeutics, and diagnostics for the SARS-CoV-2 virus – Read More


  • Submitted their proposal to the Biomedical Advanced Research and Development Authority (BARDA) to conduct a pilot clinical study on seriously and critically ill patients with respiratory compromise from COVID-19 associated pneumonitis and/or Acute Respiratory Distress Syndrome

Sorrento Therapeutics and Celularity

  • San Diego’s Sorrento Therapeutics says antibody might have ability to fight COVID-19 – Read More
  • Both companies have initiated a clinical and manufacturing collaboration to expand therapeutic use of existing cell therapy.
  • Companies have a longstanding relationship and both have expressed interest in starting clinical development efforts for anti-coronavirus allogeneic NK cell therapy immediately.
  • Looking to expand use of Celularity’s CYNK-001, an allogeneic, off-the-shelf, placental-derived Natural Killer (NK) cell therapy, to the treatment and prevention of coronavirus infections.
  • Sorrento would utilize current existing capacity in its “state-of-the-art” cGMP cell therapy manufacturing facilities in San Diego to supplement Celularity’s new cGMP facility in Florham Park, New Jersey. The combined capacity would support the rapid scale-up and sustained production of the novel cell therapy.
  • Sorrento in contact with leading scientists and local Chinese experts to discuss clinical validation and logistics requirements to fast-track CYNK-001 cell therapy available in China for this particularly urgent indication.
  • Read More – BioSpace


  • SureClinical Announces Complimentary eClinical Applications for New COVID-19 Clinical Trials – Read More


  • CSL teams up with Takeda to create virus plasma treatment – Read More

Thermo Fisher Scientific

  • Thermo Fisher, WuXi and Mayo Clinic to develop open-platform COVID-19 antibody test – Read More
  • Thermo Fisher Scientific commits to rapidly expanding testing capacity from 5 to 10 million tests per week – Read More
  • Providing genetic analysis solutions for coronavirus 2019-nCoV.
  • Thermo Fisher Scientific is an industry-leading, worldwide, trusted partner with comprehensive, end-to-end solutions for pathogen detection; scientific expertise; and the support capabilities critical to combating the current outbreak.
  • Utilizes Applied Biosystems TaqMan Assay technology to provide specific, sensitive, and accurate results.
  • Read More – ThermoFisher
  • Thermo Fisher to produce millions of coronavirus diagnostic tests


  • The 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵 𝗥𝗔𝗣𝗜𝗗 𝗖𝗨𝗥𝗘 𝗧𝗔𝗦𝗞 𝗙𝗢𝗥𝗖𝗘, a collaboration between TRACER and the University Medical Center Groningen, is offering the global community unique access to immediately generate in-human data on a potential COVID-19 treatment or vaccine by providing expertise, infrastructure and capacity
  • Read their announcement here and learn more about the task force here

TransCelerate BioPharma

  • TransCelerate BioPharma Member Companies Commit to Share COVID-19 Related Clinical Data via DataCelerate®
  • Member companies involved in partnership include AbbVie, Amgen, Astellas, Bayer, BMS, Merck, GSK, J&J, Lilly, Novartis, NovoNordisk, Pfizer, Sanofi & UCB – Read More


  • TriLink to help with trial of COVID-19 vaccine that makes more of itself – Read More
  • In operation in order to supply mission-critical products to customers, who are in turn developing life-saving medications and diagnostic tests – Read More


  • Providing research and information about COVID-19 – Read More


  • SDSU and UCSD developing low-cost, easy-to-make ventilators for COVID-19 patients – Read More
  • UCSD receives $1 million gift to increase COVID-19 testing capacity – Read More
  • Evaluating a new diagnostic testing system designed by Fluxergy that could dramatically reduce wait times for COVID-19 testing in patients – Read More
  • UC San Diego engineers and doctors team up to retrofit and 3-D print ventilators – Read More
  • Artificial Intelligence Enables Rapid COVID-19 Lung Imaging Analysis at UC San Diego Health – Read More


  • New CRISPR-Based COVID-19 Test Kit Can Diagnose Infection in Less Than an Hour – Read More

Velox Biosystems

  • Nanommune Partners With Velox Biosystems to Offer Laboratory Testing of COVID-19 Serological Assays – Read More


  • Created the Baseline COVID-19 Program, an effort to expand access to COVID-19 screening and testing. Working with health officials globally to combat the COVID-19 pandemic and expand access to reliable screening, which is critical to containment efforts – Read More


  • Biopharmaceutical company that is performing preclinical testing at UC Davis’ Mouse Biology Program to evaluate a potential vaccine and delivery system for COVID-19 – Learn More


  • The Vertex Foundation has made grants to two San Diego organizations to support the COVID-19 response in the region. This is part of $5M in donations world-wide.
    • $100,000 to Feeding San Diego to provide healthy food through emergency food distribution centers and provide food to San Diego students who rely on free meals.
    • $250,000 to Scripps Health Foundation to support their five drive-through testing centers, including at Scripps Green.
    • Read More

Vir Biotechnology

  • Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses
  • Read More


  • Using 3D models to aid developing coronavirus treatments – Read More


  • Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19 – Read More

See Also:

Biocom takes a global approach in all that we do. As a representative of over 1,300 organizations connected to California’s life science industry, we strive to provide information that could benefit this community and their pursuit of innovation. The above resources are not to be taken as medical advice but as a means to stay informed and updated.